DexCom Management

Management Kriterienprüfungen 3/4

DexCom's CEO ist Kevin Sayer , ernannt in Jun 2011, hat eine Amtszeit von 16.58 Jahren. Die jährliche Gesamtvergütung beträgt $15.71M , bestehend aus 7% Gehalt und 93% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.044% der Aktien des Unternehmens, im Wert von R$110.34M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.4 Jahre bzw. 8.4 Jahre.

Wichtige Informationen

Kevin Sayer

Geschäftsführender

US$15.7m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	7.0%
Amtszeit als Geschäftsführer	13yrs
Eigentum des Geschäftsführers	0.04%
Durchschnittliche Amtszeit des Managements	2.4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	8.4yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Kevin Sayer im Vergleich zu den Einnahmen von DexCom verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	US$639m
Dec 31 2023	US$16m	US$1m	US$542m
Sep 30 2023	n/a	n/a	US$377m
Jun 30 2023	n/a	n/a	US$358m
Mar 31 2023	n/a	n/a	US$293m
Dec 31 2022	US$15m	US$953k	US$341m
Sep 30 2022	n/a	n/a	US$244m
Jun 30 2022	n/a	n/a	US$230m
Mar 31 2022	n/a	n/a	US$258m
Dec 31 2021	US$12m	US$900k	US$217m
Sep 30 2021	n/a	n/a	US$577m
Jun 30 2021	n/a	n/a	US$562m
Mar 31 2021	n/a	n/a	US$530m
Dec 31 2020	US$14m	US$800k	US$550m
Sep 30 2020	n/a	n/a	US$231m
Jun 30 2020	n/a	n/a	US$205m
Mar 31 2020	n/a	n/a	US$148m
Dec 31 2019	US$10m	US$691k	US$101m
Sep 30 2019	n/a	n/a	-US$171m
Jun 30 2019	n/a	n/a	-US$170m
Mar 31 2019	n/a	n/a	-US$130m
Dec 31 2018	US$10m	US$601k	-US$127m
Sep 30 2018	n/a	n/a	US$43m
Jun 30 2018	n/a	n/a	-US$5m
Mar 31 2018	n/a	n/a	-US$33m
Dec 31 2017	US$8m	US$546k	-US$50m

Vergütung im Vergleich zum Markt: KevinDie Gesamtvergütung ($USD15.71M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt BR ($USD5.85M).

Entschädigung vs. Einkommen: KevinDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Kevin Sayer (66 yo)

13yrs

Amtszeit

US$15,712,244

Vergütung

Mr. Kevin Ronald Sayer has been Executive Chairman of DexCom, Inc. since July 30, 2018. Mr. Sayer has been the Chief Executive Officer of DexCom, Inc. since January 5, 2015 and as its President since June...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Kevin Sayer	Executive Chairman	13yrs	US$15.71m	0.044% $ 106.1m
Jereme Sylvain	Executive VP	4.3yrs	US$4.25m	0.0086% $ 20.9m
Jacob Leach	Executive VP & COO	1.8yrs	US$4.94m	0.065% $ 157.1m
Michael Brown	Executive VP & Chief Legal Officer	2.4yrs	US$4.34m	0.0018% $ 4.4m
Teri Lawver	Executive VP & Chief Commercial Officer	1.4yrs	US$6.53m	0.0016% $ 4.0m
Girish Naganathan	Executive VP & CTO	1.7yrs	US$4.05m	0.0014% $ 3.3m
Stacey Stewart	Senior VP & Chief Information Officer	less than a year	keine Daten	keine Daten
Sean Christensen	Director of Corporate Affairs & Head of Investor Relations	no data	keine Daten	keine Daten
Matthew Dolan	Executive Vice President of Strategy	3.3yrs	keine Daten	0% $ 0
Leverne Marsh	Executive Vice President of Marketing	less than a year	keine Daten	keine Daten
Sadie Stern	Executive VP & Chief Human Resources Officer	3.8yrs	keine Daten	0.0057% $ 13.8m
Steven Pacelli	Executive VP & MD of Dexcom Ventures	3.2yrs	US$3.02m	0.022% $ 52.1m

2.4yrs

Durchschnittliche Betriebszugehörigkeit

49yo

Durchschnittliches Alter

Erfahrenes Management: D1EX34Das Führungsteam des Unternehmens gilt als erfahren (2.4 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Kevin Sayer	Executive Chairman	16.6yrs	US$15.71m	0.044% $ 106.1m
Mark Foletta	Lead Independent Director	9.6yrs	US$393.51k	0.014% $ 34.3m
Steven Altman	Independent Director	10.6yrs	US$343.40k	0.014% $ 34.1m
Eric Topol	Independent Director	14.9yrs	US$346.49k	0.095% $ 230.1m
Nicholas Augustinos	Independent Director	14.6yrs	US$362.21k	0.0093% $ 22.6m
Bridgette Heller	Independent Director	4.8yrs	US$346.49k	0.0057% $ 13.8m
Kyle Malady	Independent Director	3.7yrs	US$343.40k	0.0039% $ 9.4m
Karen Dahut	Independent Director	3.8yrs	US$345.90k	0.0038% $ 9.2m
Richard Collins	Independent Director	7.3yrs	US$345.90k	0.0099% $ 23.9m
Rimma Driscoll	Independent Director	less than a year	US$404.72k	0% $ 0

8.4yrs

Durchschnittliche Betriebszugehörigkeit

63yo

Durchschnittliches Alter

Erfahrener Vorstand: D1EX34Die Vorstandsmitglieder gelten als erfahren (8.4 Jahre durchschnittliche Amtszeit).

DexCom Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

DexCom, Inc., Annual General Meeting, May 22, 2024

DexCom, Inc., Annual General Meeting, May 22, 2024

DexCom, Inc. Announces Appointment of Rimma Driscoll to Its Board of Directors

DexCom, Inc. Promotes Jacob S. Leach to Chief Operating Officer

DexCom, Inc. Announces Resignation of Chad M. Patterson as Executive Vice President, Global Marketing, Effective July 15, 2022

DexCom Announces Retirement of Rick Doubleday as Executive Vice President and Chief Commercial Officer

Recent updates

Dexcom Showcases Extensive Clinical Data At ADA 2024 Demonstrating the Benefit of Dexcom CGM Use Among People with Type 2 Diabetes

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects Directly to Apple Watch in the United States

Dexcom Wins Access to Dexcom One for 100,000 People Living with Type 2 Diabetes

DexCom, Inc. Provides Earnings Guidance for the Year 2024

DexCom, Inc., Annual General Meeting, May 22, 2024

DexCom, Inc., Annual General Meeting, May 22, 2024

DexCom, Inc. to Report Q1, 2024 Results on Apr 25, 2024

DexCom, Inc. Announces the FDA Clears Stelo by Dexcom – the First Glucose Biosensor

DexCom, Inc. Reiterates Revenue Guidance for the Fiscal Year 2024

DexCom, Inc. Launches Dexcom One+ Bringing Powerful, New Diabetes Management Technology to More People

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects with the t:Slim X2™ Insulin Pump by Tandem Diabetes Care in Countries Across Europe and in South Africa

DexCom, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Dexcom, Inc. Provides Revenue Guidance for the Full Year of 2024

Dexcom, Inc. Announces the Dexcom G7 Continuous Glucose Monitoring System Now Connects with the Tandem t:slim X2 Insulin Pump

DexCom, Inc. (NasdaqGS:DXCM) announces an Equity Buyback for $500 million worth of its shares.

Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring with New Clinical Data Presented at EASD

DexCom, Inc. to Report Q3, 2023 Results on Oct 26, 2023

DexCom, Inc Announces the Availability of Its Dexcom One Real-Time CGM Sensor Via Reimbursement, in France

DexCom, Inc. Announces Appointment of Rimma Driscoll to Its Board of Directors

DexCom, Inc. Increases Earnings Guidance for the Fiscal Year 2023

DexCom, Inc. to Report Q2, 2023 Results on Jul 27, 2023

Dexcom, Inc. Receives Health Canada Approval: Next-Generation Continuous Glucose Monitoring System with Unmatched Accuracy Coming to Canadians

DexCom, Inc. Updates Earnings Guidance for the Year 2025

DexCom, Inc. Reiterates Revenue Guidance for the Fiscal Year 2023

Dexcom, Inc.'s G6 Real-Time CGM System Now Available to All Clients With Type 1 Diabetes Covered Under the Non-Insured Health Benefits Program

DexCom, Inc. to Report Q4, 2022 Results on Feb 09, 2023

Dexcom, Inc. Receives FDA Clearance of Next-Generation Dexcom G7 Continuous Glucose Monitoring System

DexCom, Inc. Provides Earnings Guidance for the Year 2022

DexCom, Inc. Announces the Launch of Dexcom U

DexCom, Inc. Announces Launch of Dexcom G7 in the United Kingdom, Ireland, Germany, Austria and Hong Kong – Initiating Global Rollout of World’s Most Powerful Continuous Glucose Monitoring System

DexCom, Inc. to Report Q3, 2022 Results on Oct 27, 2022

DexCom, Inc. Promotes Jacob S. Leach to Chief Operating Officer

DexCom, Inc. Announces One Real-Time Continuous Glucose Monitoring (rt-CGM) System Available on Prescription in the UK

DexCom, Inc. (NasdaqGS:DXCM) announces an Equity Buyback for $700 million worth of its shares.

DexCom, Inc. Revises Earnings Guidance for the Full Year 2022

DexCom, Inc. Announces Resignation of Chad M. Patterson as Executive Vice President, Global Marketing, Effective July 15, 2022

DexCom, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Dexcom Says Not in Active Merger Talks

Dexcom Reportedly in Talks to Acquire Insulet

DexCom, Inc. Showcases Expanded CGM Portfolio at International ATTD Conference

Dexcom Announces Dexcom ONE, the Newest Real-Time Continuous Glucose Monitoring System, to Its Range of Scan-Free and Fingerprick†-Free Devices

DexCom, Inc. to Report Q1, 2022 Results on Apr 28, 2022

DexCom, Inc. Reiterates Earnings Guidance for the Fiscal Year 2022

Dexcom, Inc. Reports Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Fiscal Year Ended December 31, 2021; Revenue Guidance for the Fiscal Year 2022

Dexcom G6 Continuous Glucose Monitoring System Now Covered in Manitoba for Young People with Type 1 Diabetes

Dexcom, Inc. Announces Non-insured Health Benefits Program Covers Dexcom G6 Continuous Glucose Monitoring System for Children and Adolescents on Intensive Insulin Therapy

FDA Clears DexCom, Inc.'s Real-Time APIs for Third-Party Apps and Devices

DexCom, Inc.(NasdaqGS:DXCM) dropped from Russell Top 200 Index

DexCom, Inc. Announces Results of Two New Studies Illustrate Continued Momentum for Dexcom CGM, Including JAMA-Published Data on Additional Populations Who Can Benefit from the Technology

DexCom, Inc. (NasdaqGS:DXCM) acquired assets in the Netherlands, Belgium and Luxembourg from a Dexcom distributor.

DexCom, Inc. Increasing Revenue Guidance for Fiscal Year 2021

DexCom, Inc. Announces Launch of Dexcom Ventures

Everside Health's Legacy Healthstat Partners with Dexcom to Provide Continuous Glucose Monitoring for Type 2 Diabetes

DexCom, Inc. to Report Q4, 2020 Results on Feb 11, 2021

DexCom, Inc. Revises Revenue Guidance for Fiscal Year 2020

DexCom Announces Retirement of Rick Doubleday as Executive Vice President and Chief Commercial Officer

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter